Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
2495 participants
INTERVENTIONAL
2012-09-30
2018-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
\[Edit 25.3.2015: Due to difficulties in recruitment and funding, the study size is approximately 2500 subjects, with a 550 subject subgroup with more detailed examinations\]
The participants will be randomized to 3 groups with 6000 in each, with daily supplementation of either: 1) 40 µg/day (1600 IU) of vitamin D3, 2) 80 µg/day (3200 IU) of vitamin D3, or 3) placebo.
\[Edit 15.3.2015: The 2500 subjects are randomized in 3 groups, approximately 830 subjects per group.\]
Compliance, use of non-study drugs or supplements, diet, development of endpoints, and CVD and cancer risk factors will be assessed by questionnaires. Blood samples will be collected for assessment of effect modification by baseline 25-hydroxyvitamin D, as well as for future ancillary studies of genetic/biochemical hypotheses. Event data will be obtained by record linkage from the national computerized hospitalization registry.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dietary Supplementation With 25-hydroxyvitamin D3 in Older Adults
NCT01398202
Safety of Vitamin D Supplementation in Older Persons
NCT00681590
Glucose Metabolism Effects of Vitamin D Supplementation in Prediabetes
NCT01479933
The Effect of Vitamin D Supplementation on Cardiovascular Risk Factors
NCT02750293
Vitamin D Supplementation for the Prevention of Acute Respiratory Infections: a RCT in Young Finnish Men
NCT05014048
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Placebo, no Vitamin D3
Placebo
Inactive placebo
Vitamin D3 80
Vitamin D3 80 micrograms (3200 IU) per day
Vitamin D3
Vitamin D3 80 micrograms (3200 IU) per day
Vitamin D3 40
Vitamin D3 40 micrograms (1600 IU) per day
Vitamin D3
Vitamin D3 40 micrograms (1600 IU) per day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vitamin D3
Vitamin D3 40 micrograms (1600 IU) per day
Vitamin D3
Vitamin D3 80 micrograms (3200 IU) per day
Placebo
Inactive placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Women 65 years or older
Exclusion Criteria
* Cancer (except non-melanoma skin cancer).
* Any disease or state that raises a vitamin D related safety concern (such as chronic liver, thyroid or kidney disease, hypercalcemia, sarcoidosis or other granulomatous diseases such as active chronic tuberculosis or Wegener's granulomatosis).
* Use of supplements yielding vitamin D over 20 µg/day or calcium over 1200 mg/day and unwillingness to discontinue the use.
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Academy of Finland
OTHER
Juho Vainio Foundation
OTHER
Finnish Foundation for Cardiovascular Research
OTHER
Finnish Cultural Foundation
OTHER
University of Eastern Finland
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tomi-Pekka Tuomainen
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tomi-Pekka Tuomainen, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Eastern Finland
Jyrki K Virtanen, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Eastern Finland
Sari Voutilainen, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Eastern Finland
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Eastern Finland, Kuopio Campus
Kuopio, Northern Savonia, Finland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lonnroos E, Ylilauri M, Lamberg-Allardt C, Manson JE, Nurmi T, Uusitupa M, Voutilainen A, Hantunen S, Tuomainen TP, Virtanen JK. The Effect of Vitamin D3 Supplementation on the Incidence of Diagnosed Dementia Among Healthy Older Adults-The Finnish Vitamin D Trial. J Gerontol A Biol Sci Med Sci. 2025 Jun 10;80(7):glaf077. doi: 10.1093/gerona/glaf077.
Virtanen JK, Hantunen S, Kallio N, Lamberg-Allardt C, Manson JE, Nurmi T, Pihlajamaki J, Uusitupa M, Voutilainen A, Tuomainen TP. The effect of vitamin D3 supplementation on the incidence of type 2 diabetes in healthy older adults not at high risk for diabetes (FIND): a randomised controlled trial. Diabetologia. 2025 Apr;68(4):715-726. doi: 10.1007/s00125-024-06336-9. Epub 2024 Dec 2.
Virtanen JK, Hantunen S, Lamberg-Allardt C, Manson JE, Nurmi T, Uusitupa M, Voutilainen A, Tuomainen TP. The effect of vitamin D3 supplementation on atrial fibrillation in generally healthy men and women: The Finnish Vitamin D Trial. Am Heart J. 2023 Oct;264:177-182. doi: 10.1016/j.ahj.2023.05.024. Epub 2023 Jun 10.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FIND
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.